Abstract
Standard RANO and iRANO have high concordance for assessing progressive disease (PD) in patients within 6 months of immune checkpoint blockade (ICB) initiation. iRANO was beneficial in 6% (3/49) of cases later proven to be pseudoprogression (PsP), but delayed confirmation of PD by less than 3 months in 4% (2/49). PsP occurred in 12% of patients, starting at up to 7 months after initiation of ICB. Further study to define the utility of modified RANO compared with iRANO in ICB glioblastoma (GBM) patients is needed.
Introduction
Glioblastoma (GBM) is an aggressive brain cancer with poor outcomes, leading researchers to explore Immune Checkpoint Blockade (ICB) therapies. However, assessing treatment efficacy radiologically is a major challenge. Standard Response Assessment in Neuro-Oncology (RANO) criteria define progressive disease based on increased tumor size or new lesions. In immunotherapy, inflammation can mimic tumor growth on MRI—a phenomenon known as pseudoprogression (PsP). To prevent premature treatment termination, the iRANO criteria were introduced, requiring a three-month follow-up to confirm progression if worsening occurs early in treatment.
Methods
This retrospective study evaluated 49 GBM patients (7 newly diagnosed, 42 recurrent) treated with ICBs (e.g., nivolumab, pembrolizumab) at a single institution. Serial MRI scans were analyzed to quantify tumor burden using the sum of products of the two largest perpendicular diameters of enhancing lesions. Patient responses were graded using both RANO and iRANO criteria and categorized into three groups: concordant non-progressors (Group 1), discordant cases (Group 2), and concordant progressors (Group 3).
Key Results
The study found an 88% concordance rate between RANO and iRANO. iRANO successfully identified PsP in 6% (3/49) of patients, allowing them to continue therapy for an additional 42 to 82 days. However, iRANO delayed the diagnosis of true progression in 4% (2/49) of patients by 42 and 93 days. PsP was not limited to the early treatment phase, appearing as late as 7 months post-initiation.
Survival analysis demonstrated that Group 1 (concordant non-progressors) had a significantly longer median Overall Survival (OS) of 24.3 months compared to Group 3 (concordant progressors, 8.1 months). Median Progression-Free Survival (PFS) was slightly longer when assessed by iRANO (3.7 months) versus RANO (2.7 months), reflecting the built-in waiting period of the iRANO criteria.
Discussion and Conclusion
While iRANO is a valuable tool for identifying pseudoprogression and preventing the premature cessation of potentially effective immunotherapy, it carries the risk of delaying the transition to salvage therapies when treatment is truly failing. The study's limitations include a small sample size and retrospective design. Future research should compare iRANO with "modified RANO" (mRANO) to further refine the balance between detecting PsP and confirming true progression in GBM patients receiving immunotherapy.
Summary updated